What are your top takeaways in GU Cancers from ESMO 2024?

1. Tivozanib–nivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study.

This trial confirmed (along with CONTACT-03: cabozantinib +/- atezolizumab) that cont...

1. NIAGARA trial in MIBC. First immunotherapy to show improved survival in the neoadjuvant setting in bladder/urothelial carcinoma. Powles et al. present LBA5, A Randomised Phase 3 Trial of Neoadjuvant Durvalumab Plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-invasi...

My top 3 abstracts were:

1. PEACE-3
2. NIAGARA
3. AMBASSADOR

All practice-changing

1. NIAGARA - NIAGARA phase 3 trial is practice changing showing significant EFS & OS benefit with the addition of durvalumab to 4 cycles of standard Gem/Cis neoadjuvant chemotherapy with the addition of up to 8 monthly adjuvant doses of durvalumab (peri-operative strategy). The addition to durvalumab ...